Compare Stocks: ACHC, NGNE, and TSHA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHC Acadia Healthcare	$28.55 +1.3%	$30.61	$11.43 ▼ $35.83	$2.66B	0.62	3.08 million shs	147,131 shs
NGNE Neurogene	$37.41 -1.3%	$36.81	$15.93 ▼ $43.66	$749.17M	1.69	188,518 shs	12,737 shs
TSHA Taysha Gene Therapies	$5.18 -3.1%	$5.99	$2.71 ▼ $7.30	$1.68B	1.19	2.81 million shs	365,758 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHC Acadia Healthcare	+2.51%	+1.59%	-11.30%	+13.26%	+20.99%
NGNE Neurogene	-0.66%	-1.25%	+3.64%	+30.62%	+96.78%
TSHA Taysha Gene Therapies	-2.55%	-5.32%	-16.17%	-4.30%	+62.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHC Acadia Healthcare	$28.55 +1.3%	$30.61	$11.43 ▼ $35.83	$2.66B	0.62	3.08 million shs	147,131 shs
NGNE Neurogene	$37.41 -1.3%	$36.81	$15.93 ▼ $43.66	$749.17M	1.69	188,518 shs	12,737 shs
TSHA Taysha Gene Therapies	$5.18 -3.1%	$5.99	$2.71 ▼ $7.30	$1.68B	1.19	2.81 million shs	365,758 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHC Acadia Healthcare	+2.51%	+1.59%	-11.30%	+13.26%	+20.99%
NGNE Neurogene	-0.66%	-1.25%	+3.64%	+30.62%	+96.78%
TSHA Taysha Gene Therapies	-2.55%	-5.32%	-16.17%	-4.30%	+62.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHC Acadia Healthcare	2.47	Hold	$29.85	4.54% Upside
NGNE Neurogene	2.83	Moderate Buy	$83.67	123.68% Upside
TSHA Taysha Gene Therapies	3.00	Buy	$12.77	146.75% Upside

Current Analyst Ratings Breakdown

Latest ACHC, NGNE, and TSHA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	NGNE Neurogene	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$69.00 ➝ $81.00
8/12/2026	NGNE Neurogene	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$180.00 ➝ $166.00
8/12/2026	NGNE Neurogene	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$70.00 ➝ $65.00
7/30/2026	ACHC Acadia Healthcare	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$38.00 ➝ $39.00
7/30/2026	ACHC Acadia Healthcare	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$25.00 ➝ $32.00
7/29/2026	ACHC Acadia Healthcare	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/21/2026	TSHA Taysha Gene Therapies	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $13.00
7/17/2026	NGNE Neurogene	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ACHC Acadia Healthcare	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$30.00 ➝ $40.00
7/14/2026	ACHC Acadia Healthcare	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$30.00 ➝ $36.00
7/9/2026	ACHC Acadia Healthcare	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$31.00 ➝ $39.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHC Acadia Healthcare	$3.31B	0.80	$4.24 per share	6.73	$21.12 per share	1.35
NGNE Neurogene	$930K	804.81	N/A	N/A	$17.10 per share	2.19
TSHA Taysha Gene Therapies	$9.77M	172.59	N/A	N/A	$0.90 per share	5.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHC Acadia Healthcare	-$1.10B	-$12.45	N/A	16.04	8.86	-33.44%	6.19%	2.42%	11/4/2026 (Estimated)
NGNE Neurogene	-$90.35M	-$5.03	N/A	N/A	N/A	N/A	-45.10%	-41.00%	11/12/2026 (Estimated)
TSHA Taysha Gene Therapies	-$109M	-$0.42	N/A	N/A	N/A	N/A	-56.19%	-41.84%	11/3/2026 (Estimated)

Latest ACHC, NGNE, and TSHA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	NGNE Neurogene	-$1.42	-$1.53	-$0.11	-$1.53	N/A	N/A
8/11/2026	Q2 2026	TSHA Taysha Gene Therapies	-$0.1133	-$0.13	-$0.0167	-$0.13	$0.68 million	N/A
7/28/2026	Q2 2026	ACHC Acadia Healthcare	$0.3463	$0.38	+$0.0337	$0.12	$844.19 million	$865.84 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHC Acadia Healthcare	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
TSHA Taysha Gene Therapies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHC Acadia Healthcare	1.20	1.57	1.57
NGNE Neurogene	N/A	10.65	10.64
TSHA Taysha Gene Therapies	0.13	17.76	17.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHC Acadia Healthcare	N/A
NGNE Neurogene	52.37%
TSHA Taysha Gene Therapies	77.70%

Insider Ownership

Company	Insider Ownership
ACHC Acadia Healthcare	1.20%
NGNE Neurogene	11.68%
TSHA Taysha Gene Therapies	3.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHC Acadia Healthcare	25,000	93.10 million	91.98 million	Optionable
NGNE Neurogene	90	20.01 million	17.67 million	Optionable
TSHA Taysha Gene Therapies	180	325.83 million	314.50 million	Optionable

ACHC, NGNE, and TSHA Headlines

Recent News About These Companies

These 3 Risky Stocks Could Be Sitting on 100% Upside (TSHA)

...

September 7 at 11:35 AM | marketbeat.com

Wellington Management Group LLP Acquires 3,349,244 Shares of Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Bank of New York Mellon Corp Purchases New Position in Taysha Gene Therapies, Inc. $TSHA

September 6, 2026 | marketbeat.com

Seven Fleet Capital Management LP Has $9.94 Million Holdings in Taysha Gene Therapies, Inc. $TSHA

September 5, 2026 | marketbeat.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4, 2026 | globenewswire.com

Bank of America Corp DE Has $7.50 Million Stake in Taysha Gene Therapies, Inc. $TSHA

August 26, 2026 | marketbeat.com

Taysha Gene Therapies Earnings Call Highlights Pivotal Progress

August 23, 2026 | tipranks.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down - Should You Sell?

August 20, 2026 | marketbeat.com

Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call

August 18, 2026 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages

August 18, 2026 | marketbeat.com

Wells Fargo Issues a Buy Rating on Taysha Gene Therapies (TSHA)

August 14, 2026 | theglobeandmail.com

Taysha Gene Therapies (TSHA) After Rett Trial Progress And Catalent Expansion Is The Undervalued Case Stronger

August 13, 2026 | finance.yahoo.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.6% - Here's Why

August 13, 2026 | marketbeat.com

Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026 | finanznachrichten.de

Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...

August 12, 2026 | finance.yahoo.com

Taysha outlines REVEAL 6-month interim analysis and FDA feedback in H1 2027 while targeting PPQ completion in Q4 2026

August 12, 2026 | seekingalpha.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Down Following Weak Earnings

August 12, 2026 | marketbeat.com

Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA

August 12, 2026 | marketbeat.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

August 11, 2026 | seekingalpha.com

Taysha Gene Therapies Q2 Earnings Call Highlights

August 11, 2026 | marketbeat.com

Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

August 11, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHC, NGNE, and TSHA Company Descriptions

Acadia Healthcare NASDAQ:ACHC

$28.55 +0.36 (+1.28%)

As of 10:48 AM Eastern

Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.

Neurogene NASDAQ:NGNE

$37.40 -0.48 (-1.25%)

As of 10:47 AM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Taysha Gene Therapies NASDAQ:TSHA

$5.18 -0.17 (-3.09%)

As of 10:47 AM Eastern

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHC, NGNE, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHC, NGNE, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHC, NGNE, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHC, NGNE, and TSHA Company Descriptions

Acadia Healthcare NASDAQ:ACHC

Neurogene NASDAQ:NGNE

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACHC, NGNE, and TSHA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACHC, NGNE, and TSHA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACHC, NGNE, and TSHA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHC, NGNE, and TSHA Company Descriptions

Acadia Healthcare NASDAQ:ACHC

Neurogene NASDAQ:NGNE

Taysha Gene Therapies NASDAQ:TSHA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools